Disease; Multiple Sclerosis; Update; Monoclonal antibodies; modifying therapy; Humans; Young Adult; Multiple Sclerosis/therapy; Disease-modifying therapy; Medicine (all)
Abstract :
[en] Multiple sclerosis is still a severe disease potentially associated with a short- or long-term disability in young adults. Since a few years therapeutic progresses are considerable. New drugs and new therapy rationale considerably improved our knowledge and patient's care. Early treatment is a key within dedicated specialized and multidisciplinary units. Clinical and neuroradiological no evidence of disease activity (NEDA) is a goal, which is more often reached. Patient's evolution and follow-up is completely changed in recent years with more efficacy. [fr] La sclérose en plaques (SEP) reste une maladie grave du système nerveux central (SNC), potentiellement responsable d’un handicap, physique ou non, à moyen et long termes, chez des adultes jeunes. Les progrès thérapeutiques au cours des dernières années ont été considérables grâce à l’avènement de nouvelles molécules, mais aussi, et peut-être surtout, de schémas thérapeutiques nettement plus performants. Les progrès des connaissances en immunologie ont eu un impact majeur dans ce domaine. La prise en charge précoce des patients au sein d’unités intégrées et multidisciplinaires est une étape essentielle qui permet de guider l’utilisation rationnelle des médicaments. L’obtention d’une stabilité clinique et neuroradiologique est un défi qui est, de plus en plus souvent, relevé avec un bénéfice majeur pour les patients.
Disciplines :
Neurology
Author, co-author :
Dive, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Dauby, Solène ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Lommers, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Hansen, Isabelle ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Maquet, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Language :
French
Title :
Actualités thérapeutiques dans la sclérose en plaques.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-73.
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis : The 2013 revisions. Neurology 2014;83:278-86.
Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019;321:175-87.
Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019;76:536-41.
Saposnik G, Montalban X, Selchen D, et al. Therapeutic inertia in multiple sclerosis care : A study of Canadian neurologists. Front Neurol 2018;9:781.
Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER) : A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56.
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107.
Guarnera C, Bramanti P, Mazzon E. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther 2017;11:2193-207.
Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the treatment era'. Nat Rev Neurol 2015;11:280-9.
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
Schwab N, Schneider-Hohendorf T, Melzer N. Natalizumabassociated PML : challenges with incidence, resulting risk, and risk stratification. Neurology 2017;88:1197-205.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS) : A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1075-84.
Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND) : A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 2018;17:405-15.
Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014;261:1170-7.
Hatcher SE, Waubant E, Nourbakhsh B, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 2016;73:790-4.
Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis : A randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy : A randomised controlled phase 3 trial. Lancet 2012;380:1829-39.
Ziemssen T, Thomas K. Alemtuzumab in the long-Term treatment of relapsing-remitting multiple sclerosis : An update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017;10:343-59.
Sellner J, Rommer PS. Immunological consequences of immune reconstitution therapy in multiple sclerosis : A systematic review. Autoimmun Rev 2020:102492.
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis : results from the randomized extension trial of the CLARITY study. Mult Scler 2018;24:1594-604.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-34.
Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209-20.
Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis : A randomized clinical trial. JAMA 2019;321:165-74.
Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-Antibody disease : A UK study. Brain 2017;140:3128-38.
Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med 2018;379:1017-27.
